The approval of Amtagvi represents the culmination of scientific and clinical research efforts leading to a novel T cell immunotherapy for patients with limited treatment options, said Dr. Peter Marks.
T cells are part of the immune system. While they can typically help fight cancer, they tend to become dysfunctional inside tumors.
[
add
]
[
|
|
...
]